Inventage Lab Inc is a Korea-based company principally engaged in the pharmaceutical business. The Company owns the platforms applied to the development and mass production of long-acting injections and drug delivery of genetic materials. The Company is engaged in the research, manufacture and sale of human medicines used for male pattern baldness, dementia, prostate cancer and others. It is also engaged in the research, manufacture and sale of veterinary medicines such as combination drugs, chemical castration agents and others.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
07/07/26	₩38,100.00	+1.46%	59,871
06/07/26	₩37,550.00	-1.44%	30,272
03/07/26	₩38,100.00	-2.06%	51,904
02/07/26	₩38,900.00	-9.64%	94,922
01/07/26	₩43,050.00	+8.99%	135,243

End-of-day quote Korea S.E.

More quotes

Income Statement and Estimates

More financial data

End-of-day quote Korea S.E. Other stock markets 07/07/2026			5-day change	1st Jan Change
38,100.00 ^KRW	+1.46%		-4.15%	-54.75%

03-15	Quratis Inc. announced that it has received KRW 10.000000167 billion in funding from Inventage Lab, Inc.	CI
03-15	Inventage Lab, Inc. announced that it has received KRW 89.99724455 billion in funding from a group of investors	CI

Market Cap	506B 334M 292M 269M 250M 474M 31.7B 482M 3.23B 1.26B 15.64B 1.25B 1.23B 54.07B	P/E 2024	-11.5x	P/E 2025	-110x
Enterprise Value	501B 330M 289M 266M 247M 469M 31.36B 476M 3.2B 1.24B 15.48B 1.24B 1.21B 53.5B	EV / Sales 2024	106x	EV / Sales 2025	356x
Free-Float	78.93%	Yield 2024 *	-	Yield 2025	-

03-15	Quratis Inc. announced that it has received KRW 10.000000167 billion in funding from Inventage Lab, Inc.	CI
03-15	Inventage Lab, Inc. announced that it has received KRW 89.99724455 billion in funding from a group of investors	CI
03-08	Inventage Lab, Inc. announced that it has received KRW 8.5 billion in funding	CI
03-05	Inventage Lab, Inc. announced that it expects to receive KRW 37.25 billion in funding from a group of investors	CI
03-05	Inventage Lab, Inc. announced that it expects to receive KRW 8.5 billion in funding	CI
03-05	Inventage Lab, Inc. announced that it expects to receive KRW 52.74724455 billion in funding from a group of investors	CI
03-05	Quratis Inc. announced that it expects to receive KRW 10.000000167 billion in funding from Inventage Lab, Inc.	CI
02-25	Inventage Lab, Inc. agreed to acquire an additional 12.79% stake in Quratis Inc. for KRW 13.5 billion.	CI
12-10	Inventage Lab Seeks Approval for Phase 2 Trial of Alopecia Drug in Australia	MT
22/09/25	Inventage Lab, Inc.(KOSDAQ:A389470) added to S&P Global BMI Index	CI
11/03/25	Inventage Lab, Inc. announced that it has received KRW 9.9999925 billion in funding from PEACE to S KOREA Co., Ltd	CI
11/03/25	Quratis Inc. announced that it has received KRW 10.0329 billion in funding from Inventage Lab, Inc.	CI
20/02/25	Quratis Inc. announced that it has received KRW 15 billion in funding from Inventage Lab, Inc.	CI

1 day	+1.46%
1 week	-4.15%
Current month	-3.54%
1 month	-18.94%
3 months	-35.42%
6 months	-55.54%
Current year	-54.75%

Inventage Lab, Inc. Share Price

Stocks

A389470

KR7389470006

Pharmaceuticals

Valuation: Inventage Lab, Inc.

Chart: Inventage Lab, Inc.

Latest news : Inventage Lab, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Inventage Lab, Inc.

Latest insider transactions

Other Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

1 week	36,000	46,200
1 month	33,600	49,350
Current year	33,600	101,700
1 year	28,550	101,700
3 years	8,800	101,700
5 years	8,440	101,700
10 years	8,440	101,700

Manager	Title	Age	Since
Ju-Hee Kim CEO	Chief Executive Officer	52	13/05/2015
Byeong-Yul Jeong DFI	Director of Finance/CFO	55	-
Chan-Hee Jeon CTO	Chief Tech/Sci/R&D Officer	57	-

Director	Title	Age	Since
Ju-Hee Kim BRD	Director/Board Member	52	13/05/2015
Choong-Ho Ryu BRD	Director/Board Member	56	-
Chan-Hee Jeon BRD	Director/Board Member	57	-

Date	Insider	Type	Quantity	% Market Cap.
07/08/25	Dong Seok Park	Fiscal year	8,000	0.0796%
07/08/25	Dong Seok Park	Fiscal year	8,000	0.0796%
07/08/25	Se Yeon Kim	Fiscal year	10,000	0.0996%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
INVENTAGE LAB, INC.	+1.46%	-4.15%	+24.71%	+318.68%	334M
ELI LILLY AND COMPANY	+2.96%	+3.01%	+59.87%	+173.31%	1,102B
JOHNSON & JOHNSON	+3.05%	+5.23%	+72.11%	+67.81%	643B
ABBVIE INC.	-0.04%	+1.20%	+35.72%	+87.93%	450B
ROCHE HOLDING AG	+0.93%	-2.07%	+27.62%	+22.57%	336B
NOVARTIS AG	-0.75%	-0.79%	+28.65%	+47.90%	288B
NOVO NORDISK A/S	-2.63%	+1.02%	-27.97%	-40.82%	222B
AMGEN INC.	+0.45%	+1.65%	+25.65%	+68.35%	199B
GILEAD SCIENCES, INC.	+5.21%	+7.93%	+21.99%	+83.23%	169B
PFIZER INC.	+1.48%	-0.04%	-4.64%	-32.25%	137B
Average	+0.47%	+0.65%	+26.37%	+79.67%	354.55B
Weighted average by Cap.	+0.24%	+1.85%	+41.72%	+87.38%

	2024	2025
Net sales	1.78B 1.18M 1.03M 949K 880K 1.67M 112M 1.7M 11.38M 4.43M 55.13M 4.42M 4.32M 191M	2.94B 1.94M 1.7M 1.56M 1.45M 2.75M 184M 2.8M 18.76M 7.3M 90.87M 7.28M 7.13M 314M
Net income	-17B -11.22M -9.82M -9.05M -8.39M -15.92M -1.06B -16.18M -109M -42.2M -526M -42.13M -41.21M -1.82B	-8.46B -5.58M -4.89M -4.5M -4.17M -7.92M -530M -8.05M -54M -21M -262M -20.96M -20.51M -904M
Net Debt	-23.96B -15.82M -13.84M -12.76M -11.83M -22.45M -1.5B -22.81M -153M -59.5M -741M -59.4M -58.11M -2.56B	-5.33B -3.52M -3.08M -2.84M -2.63M -4.99M -334M -5.07M -34.01M -13.23M -165M -13.2M -12.92M -569M